Geographical distribution of complement receptor type 1 variants and their associated disease risk

Thaisa Lucas Sandri1,2*, Selorme Adukpo1,3*, Dao Phuong Giang4,6, Christian N. Ngue et1, Fabiana Antunes Andrade2, Hoang van Tong2,6, Nguyen Linh Toan5,6, Le Huu Song4,5, Preetham Elumalai7, Kumarasamy Thangaraj8, Vijaya Lakshmi Valluri9, Francine Ntoumi10, Christian G. Meyer1,5,11, Iara Jose de Messias Reason2, Peter G. Kremsner1, Thirumalaisamy P. Velavan1,5,10,11*

1 Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany, 2 Laboratory of Molecular Immunopathology, Federal University of Paraná, Curitiba, Brazil, 3 Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana, 4 108 Military Central Hospital, Hanoi, Vietnam, 5 Vietnamese - German Center for Medical Research, Hanoi, Vietnam, 6 Vietnam Military Medical University, Hanoi, Vietnam, 7 Kerala University of Fisheries and Oceanic Studies, Kochi, India, 8 CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India, 9 LEPPA- Blue Peter Public Health and Research Center, Hyderabad, India, 10 Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo, 11 Duy Tan University, Da Nang, Vietnam

☯ These authors contributed equally to this work.
* velavan@medizin.uni-tuebingen.de

Abstract

Background

Pathogens exert selective pressure which may lead to substantial changes in host immune responses. The human complement receptor type 1 (CR1) is an innate immune recognition glycoprotein that regulates the activation of the complement pathway and removes opsonized immune complexes. CR1 genetic variants in exon 29 have been associated with expression levels, C1q or C3b binding and increased susceptibility to several infectious diseases. Five distinct CR1 nucleotide substitutions determine the Knops blood group phenotypes, namely Knab/b, McCab/b, SI1/SI2, SI4/SI5 and KCAM+/-.

Methods

CR1 variants were genotyped by direct sequencing in a cohort of 441 healthy individuals from Brazil, Vietnam, India, Republic of Congo and Ghana.

Results

The distribution of the CR1 alleles, genotypes and haplotypes differed significantly among geographical settings (p<0.001). CR1 variants rs17047660A/G (McCab/b) and rs17047661A/G (SI1/SI2) were exclusively observed to be polymorphic in African populations compared to the groups from Asia and South-America, strongly suggesting that these two SNPs may be subjected to selection. This is further substantiated by a high linkage disequilibrium between the two variants in the Congolese and Ghanaian populations. A total of nine CR1 haplotypes...
were observed. The CR1*AGAATA haplotype was found more frequently among the Brazilian and Vietnamese study groups; the CR1*AGAATG haplotype was frequent in the Indian and Vietnamese populations, while the CR1*AGAGTG haplotype was frequent among Congolese and Ghanaian individuals.

**Conclusion**

The African populations included in this study might have a selective advantage conferred to immune genes involved in pathogen recognition and signaling, possibly contributing to disease susceptibility or resistance.

**Introduction**

Complement receptor type 1 (CR1) is widely recognized to play a role in disease pathophysiology, diagnosis, prognosis and in therapy [1]. The gene encoding human CR1 is located on chromosome 1 (1q32.2; OMIM 120620) [2–4]. CR1 belongs to the regulator of complement activation family (RCA) and is a transmembrane glycoprotein (single chain type 1), which occurs either in membrane-bound or soluble forms [2,5]. CR1 is predominantly involved in the transport of circulating immune complexes to the reticuloendothelial system.

CR1 acts as a regulator in the three pathways of the complement system [2], namely the classical, the lectin and the alternative pathway. It enhances phagocytosis of opsonized particles together with the complement components C3b, C4b, C1q, mannos-binding lectin and ficolin-2, thereby facilitating clearance of opsonized immune complexes. In the presence of Factor I, CR1 suppresses the complement cascade by inactivating C3b and C4b [6]. CR1 comprises of 30 short complement regulator (SCR) domains, known as complement control protein repeats (CCPs). Four protein isoforms have been identified based on their molecular weight and the number of CR1 exons [3]. Groups of seven CCPs are organized into four long homologous repeats (LHRs A to D) [7,8].

CR1 is also expressed on cells involved in both innate and adaptive immune responses [9–11]. The erythrocyte CR1 binds to circulating immune complexes and to complement-coated particles to transport them to the liver or spleen for subsequent phagocytosis [2,3]. CR1 deficient mice showed decreased and delayed IgM and IgG responses to West-Nile virus, thus increasing mortality [12]. Moreover, in vitro studies have shown that CR1 has distinct adjuvant properties [13–16], probably due to its involvement in uptake of antigen by antigen-presenting cells [17].

Three types of polymorphisms have been characterized in the CR1 gene, namely those generating size variants, those resulting in copy number differences on red blood cells and polymorphisms forming the Knops blood group antigens [1,18]. Five distinct CR1 nucleotide substitutions determine the Knops blood group phenotypes: Knops (rs41274768, Kn<sup>a/b</sup>, p.N1540S), McCoy (rs17047660, McC<sup>a/b</sup>, p.K1590E), Swain-Langley/Villien (rs17047661, Sl1/Sl2, p.R1601G), Swain-Langley (rs4844609, Sl4/Sl5, p.T1610S), and the KCAM antigens (rs6691117, KCAM+/-, p.I1615V) [19–23].

In the process of pathogen evasion from the host’s immune system, pathogens bind to complement receptors and other regulatory proteins to facilitate their uptake by host cells. This may considerably downregulate and impair the function of the complement system [24]. For instance, CR1 has been reported to facilitate entry of intracellular pathogens into host cells and CR1 protein levels are associated with disease susceptibility. Among protozoan parasites,
CR1 mediates immune adherence of intracellular *Leishmania* amastigotes [25] to present them to macrophages, the preferred habitat of *Leishmania* [26,27]. Low CR1 levels were associated with a decreased degree of opsonisation in patients with chronic *Trypanosoma cruzi* infection [28]. Among viral infections, CR1 has been shown to be a secondary receptor for Epstein-Barr virus (EBV) [29] and to expedite the entry of EBV into cells [30,31]. CR1 is associated with the pathogenesis caused by SARS-CoV [32], adenoviruses [33] and other viral infections such as HIV and HCV [30].

The present study utilized samples from five populations originating from Brazil, Ghana, Republic of Congo, India and Vietnam and aimed to assess the distribution of the different Knops blood group antigens and functional CR1 genetic variants [rs17259045, rs41274768 (Kn<sup>ab</sup>), rs17047660 (McC<sup>ab</sup>), rs17047661 (Sl1/SI2), rs4844609 (Sl4/SI5), rs6691117 (KCAM+/−)] in exon 29 that were involved in pathogen recognition and signaling, possibly contributing to disease susceptibility or resistance.

**Methods**

**Ethics statement**

The study was approved by the Ethics Committee of the Hospital de Clínicas in Curitiba, Brazil, the institutional Review Board of the Tran Hung Dao Hospital, Hanoi, Vietnam, the Ethics Committee of the CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India, Ethics Committee of the LEPRA-Blue Peter Public Health and Research Centre; the Ethics Committee of the Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo and the Ethics Committee of the Noguchi Memorial Institute for Medical Research, Ghana. Informed written consent was received from all studied participants (consent from parents if the participant was under 18 years old).

**Study population**

A total of 441 DNA samples from healthy individuals were utilized. Investigations were carried out in populations from Brazil [n = 102; mean age 51±7; 48% (49/102) were female and 52% (53/102) male], Ghana [n = 77; mean age 5±3; 45% (28/62) were female and 55% (34/62) male], Republic of Congo [n = 77; mean age 3±3; 49% (38/77) were female and 51% (39/77) male], India [n = 86; mean age 32±18; 39% (30/78) were female and 61% (48/78) male] and Vietnam [n = 99; mean age 26±5; 40% (36/89) were female and 60% (53/89) male].

**CR1 genotyping**

In order to assess the distribution of six functional variants [rs17259045, rs41274768 (Kn<sup>ab</sup>), rs17047660 (McC<sup>ab</sup>), rs17047661 (Sl1/SI2), rs4844609 (Sl4/SI5), rs6691117 (KCAM+/−)], the complete CR1 exon 29 including their intron-exon boundaries was screened by direct sequencing in the 441 DNA samples (Table 1). A fragment of 884 bp in exon 29 of the CR1 gene was amplified by polymerase chain reaction (PCR) using the CR1 locus specific primer CR1F (5′-TCT TCA TAA ATA ATG CCA GAA GTG G-3′) and CR1R (5′-TGC CAA TTT CAT AGT CCT TAT ACA C-3′). PCR amplifications were carried out in a 25 μl volume of reaction mixture containing 10X PCR buffer, 3.0 mM MgCl₂, 0.2 mM dNTPs, 0.2 μM of each primer, 1 unit of Taq polymerase (Qiagen GmbH, Hilden, Germany) and 20 ng of genomic DNA on a TProfessional Basic Thermocycler (Biometra GmbH, Göttingen, Germany). Cycling parameters were initial denaturation at 94°C for 5 minutes followed by 40 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and elongation at 72°C for 1 minute, and a final elongation step at 72°C for 10 minutes. PCR fragments were stained with SYBR
Table 1. Genotypes and allele frequencies of the investigated six CR1 variants among world populations.

| CR1 SNPs   | Brazilian n = 102 (%) | Vietnamese n = 99 (%) | Indian n = 86 (%) | Congolese n = 77 (%) | Ghanaian n = 77 (%) | p value |
|------------|-----------------------|-----------------------|------------------|----------------------|---------------------|---------|
| rs17259045A/G | AA 82 (80)           | 99 (100)              | 84 (98)          | 77 (100)             | 77 (100)            | < 0.002 |
|            | AG 20 (20)            | 0                     | 2 (2)            | 0                    | 0                   |         |
|            | GG 0                  | 0                     | 0                | 0                    | 0                   |         |
|            | A 184 (90)            | 198 (100)             | 170 (99)         | 154 (100)            | 154 (100)           |         |
|            | G 20 (10)             | 0                     | 2 (1)            | 0                    | 0                   |         |
| rs41274768G/A | GG 96 (96)            | 99 (100)              | 85 (99)          | 77 (100)             | 77 (100)            | NA      |
|            | GA 4 (4)              | 0                     | 1 (1)            | 0                    | 0                   |         |
|            | AA 0                  | 0                     | 0                | 0                    | 0                   |         |
|            | G 200 (98)            | 198 (100)             | 171 (99)         | 154 (100)            | 154 (100)           |         |
| rs17047660A/G | AA 99 (98)            | 99 (100)              | 86 (100)         | 46 (60)              | 35 (45)             | <0.0001 |
|            | AG 2 (2)              | 0                     | 0                | 27 (35)              | 34 (44)             |         |
|            | GG 0                  | 0                     | 0                | 4 (5)                | 8 (10)              |         |
|            | A 200 (99)            | 198 (100)             | 172 (100)        | 119 (77)             | 104 (67)            |         |
|            | G 2 (1)               | 0                     | 0                | 35 (23)              | 50 (33)             |         |
| rs17047661A/G | AA 94 (93)            | 99 (100)              | 86 (100)         | 7 (9)                | 7 (9)               | <0.01   |
|            | AG 7 (7)              | 0                     | 0                | 31 (40)              | 28 (36)             |         |
|            | GG 0                  | 0                     | 0                | 39 (51)              | 42 (55)             |         |
|            | A 195 (96)            | 198 (100)             | 172 (100)        | 45 (29)              | 42 (26)             |         |
|            | G 7 (4)               | 0                     | 0                | 109 (71)             | 112 (74)            |         |
| rs4844609T/A | TT 99 (98)            | 99 (100)              | 86 (100)         | 77 (100)             | 77 (100)            | NS      |
|            | TA 2 (2)              | 0                     | 0                | 0                    | 0                   |         |
|            | AA 0                  | 0                     | 0                | 0                    | 0                   |         |
|            | T 200 (99)            | 198 (100)             | 172 (100)        | 154 (100)            | 154 (100)           |         |
|            | A 2 (1)               | 0                     | 0                | 0                    | 0                   |         |
| rs6691117A/G | AA 61 (60)            | 37 (37)               | 21 (24)          | 0                    | 3 (4)               | < 0.006 |
|            | AG 33 (33)            | 53 (53)               | 39 (46)          | 19 (25)              | 10 (13)             |         |
|            | GG 7 (7)              | 9 (9)                 | 26 (30)          | 58 (75)              | 64 (83)             |         |
|            | A 155 (77)            | 127 (64)              | 81 (47)          | 19 (12)              | 16 (9)              |         |
|            | G 47 (23)             | 71 (36)               | 91 (53)          | 135 (88)             | 138 (91)            |         |

NS, not significant; NA, not applicable

https://doi.org/10.1371/journal.pone.0175973.t001

Safe DNA Gel Stain (Invitrogen, Carlsbad, USA) and visualized on 1.5% agarose gels. PCR products were subsequently purified using Exo-SAP-IT (USB, Affymetrix, Santa Clara, CA, USA) and the purified products were directly used as templates for sequencing using the Big-Dye terminator v. 1.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) on an ABI 3130XL DNA sequencer according to the manufacturer’s instructions. DNA polymorphisms were identified by assembling the sequences with the reference sequence of the CR1 (NM_000573) using Geneious v9.1.4 software (Biomatters Ltd, Auckland, New Zealand) and reconfirmed visually from their respective electropherograms.

Statistical analysis

Statistical analyses were performed using the GraphPad Prism 3.0 software package (GraphPad Software, La Jolla, CA, USA) and Stata 12.0 (StataCorp, College Station, TX, USA). Normal Chi square and two tailed Fisher’s exact tests were calculated to determine the differences of
genotype, allele and haplotype frequencies among the different ethnicities. Genotype and allele frequencies were determined by simple gene counting and haplotypes were reconstructed by using the expectation-maximum (EM) algorithm as implemented in the Arlequin v3.5.2.2 software (http://cmpg.unibe.ch/software/arlequin35/Arl35Downloads.html). The significance of deviations from Hardy Weinberg equilibrium was tested using the approach of Guo and Thompson random-permutation procedure implemented in Arlequin v. 3.5.2.2 software. Linkage disequilibrium (LD) analysis was performed using the Haploview v. 3.2 program (https://www.broadinstitute.org/haploview/downloads). The level of significance was set to a p-value of <0.05.

Results

The frequencies of CR1 genotypes in the five populations were in Hardy Weinberg equilibrium (p>0.05). The allele and genotype frequencies of the CR1 SNPs rs17259045, rs17047660 (McC<sup>a/b</sup>), rs17047661 (Sl1/Sl2) and rs6691117 (KCAM+/-) differed significantly among the groups (p<0.01) (Table 1). Genotype frequencies of the CR1 variants rs41274768 (Kn<sup>a/b</sup>) and rs4844609 (Sl4/Sl5) did not differ. The rs17259045AG genotype and the rs17259045G allele were more frequent in the Brazilian population. Moreover, the G carriers (AG and GG) and the G allele of variants rs17047660 (McC<sup>a/b</sup>), rs17047661 (Sl1/Sl2) and rs6691117 (KCAM+/-) were observed more commonly among the two African populations (Republic of Congo, Ghana). Interestingly, among Congolese and Ghanaian individuals the minor allele of SNPs rs17259045A/G, rs41274768G/A (Kn<sup>a/b</sup>) and rs4844609T/A (Sl4/Sl5) did not occur at all; this allele was observed exclusively in Brazilian individuals. Except for rs6691117 (KCAM+/-), the Vietnamese population was monomorphic. The Indian group was monomorphic for three of the SNPs, but not for rs17259045, rs41274768 (Kn<sup>a/b</sup>) and rs6691117 (KCAM+/-). Brazilian individuals were polymorphic for all SNPs (Table 1). The Knops blood antigen distribution among the studied populations is summarized in Table 2.

Haplotypes were reconstructed from the six CR1 variants. A total of nine haplotypes were observed. The haplotype distributions are summarized in Table 3 and Fig 1. The CR1<sup>AGAATA</sup> haplotype was more frequent among the Brazilian and Vietnamese populations; CR1<sup>AGAATG</sup> occurred frequently among the Indian and Vietnamese groups, while CR1<sup>AGAGTG</sup> was observed frequently among Congolese and Ghanaian individuals. The

Table 2. Knops blood group antigens distribution among world populations.

| CR1 variants | Amino acid substitution | Knops blood antigens | Brazil n = 202 (%) | Vietnam n = 198 (%) | India n = 172 (%) | Congo n = 154 (%) | Ghana n = 154 (%) | p value |
|--------------|--------------------------|----------------------|---------------------|---------------------|------------------|-----------------|-----------------|--------|
| rs41274768   | V1561M                   | Kn<sup>a</sup>       | 200 (98)            | 198 (100)           | 171 (99.4)       | 154 (100)       | 154 (100)       | NS     |
|              |                          | Kn<sup>b</sup>       | 4 (2)               | 0                   | 1 (0.6)          | 0               | 0               |        |
| rs17047660   | K1590E                   | McC<sup>a</sup>      | 200 (99)            | 198 (100)           | 172 (100)        | 119 (77.3)      | 104 (67.5)      | <0.0001|
|              |                          | McC<sup>b</sup>      | 2 (1)               | 0                   | 0                | 35 (22.7)       | 50 (32.4)       |        |
| rs17047661   | R1601G                   | Sl1                  | 195 (96.5)          | 198 (100)           | 172 (100)        | 45 (29.2)       | 42 (27.3)       | <0.0001|
|              |                          | Sl2                  | 7 (3.5)             | 0                   | 0                | 109 (70.8)      | 112 (72.7)      |        |
| rs4844609    | T1610S                   | Sl4                  | 200 (99)            | 198 (100)           | 172 (100)        | 154 (100)       | 154 (100)       | NA     |
|              |                          | Sl5                  | 2 (1)               | 0                   | 0                | 0               | 0               |        |
| rs6691117    | I1615V                   | KCAM+                | 155 (76.7)          | 127 (64.1)          | 81 (47.1)        | 19 (12.3)       | 16 (10.4)       | <0.0001|
|              |                          | KCAM−                | 47 (23.3)           | 71 (35.9)           | 91 (52.9)        | 135 (87.7)      | 138 (89.6)      |        |

NS, not significant; NA, not applicable

https://doi.org/10.1371/journal.pone.0175973.t002
CR1 variants in different world populations

CR1 variants in different world populations

Table 3. Reconstructed CR1 haplotype distribution among world populations.

| CR1 haplotypes (+4659/+4721/+4808/+4841/+4868/+4883) | Brazil n = 202 (%) | Vietnam n = 198 (%) | India n = 172 (%) | Congo n = 154 (%) | Ghana n = 154 (%) | p value |
|-------------------------------------------------|------------------|-------------------|----------------|----------------|----------------|---------|
| CR1*AGAATA                                      | 130 (64)         | 127 (64)          | 79 (45.9)      | 19 (12.3)      | 14 (9)         | <0.0005 |
| CR1*AGAATG                                      | 39 (19)          | 71 (36)           | 90 (52.3)      | 26 (17)        | 26 (16)        | <0.0016 |
| CR1*GGAATA                                      | 19 (9)           | 0                 | 0              | 0              | 0              | NA      |
| CR1*AAGGTG                                      | 1 (0.5)          | 0                 | 0              | 35 (22.7)      | 51 (33)        | <0.0001 |
| CR1*AAGAGTG                                     | 3 (1.5)          | 0                 | 0              | 74 (48)        | 63 (41)        | <0.0001 |
| CR1*AATAATG                                     | 4 (2)            | 0                 | 1 (0.6)        | 0              | 0              | NA      |
| CR1*AAGATA                                      | 1 (0.5)          | 0                 | 2 (1.2)        | 0              | 0              | NS      |
| CR1*AAGAAA                                      | 2 (1)            | 0                 | 0              | 0              | 0              | NA      |
| CR1*AAGAGTA                                     | 3 (1.5)          | 0                 | 0              | 0              | 0              | NA      |

NS, not significant; NA, not applicable

https://doi.org/10.1371/journal.pone.0175973.t003

CR1*AGGGTG and CR1*AGAGTG haplotypes were observed only in Brazil and Africa, being far more frequent among the Congolese and Ghanaian groups. Interestingly, CR1*GGAATA was exclusively observed in the Brazilian population. Linkage disequilibrium (LD) analysis between SNPs revealed medium levels of LD for SNPs rs17047661 (Sl1/Sl2) and rs6691117 (KCAM+/-) and for rs17047660 (McC^a/b) and rs17047661 (Sl1/Sl2) in the Congolese and Ghanaian study groups (Fig 2).

Fig 1. Distribution of CR1 haplotypes in world populations.

https://doi.org/10.1371/journal.pone.0175973.g001
Discussion

Pathogens exert strong selective pressure on the human host, leading to substantial changes in host immune regulation thereby evading immune responses. This study utilized samples from population exposed to diverse infectious diseases, where a strong selective pressure is exerted by these infectious pathogens on the human immune locus. The samples utilized in this study are from different case-control cohorts investigated for possible associations of CR1 variants with different infectious diseases (unpublished data). Brazilian, Vietnamese and Indian samples utilized in this study are from an endemic area to Chagas disease, viral hepatitis and leprosy respectively. The Republic of Congo and Ghanaian samples are from malaria holoendemic sites.

CR1 genetic variants in exon 29 are associated with CR1 expression levels, C1q or C3b binding activity and increased susceptibility to various infectious diseases. This study investigated the entire exon 29 of CR1 in five diverse populations in order to assess the distribution of Knops blood group antigens and the distinct functional CR1 SNPs. Such studies on geographically diverse populations can provide insights on how these CR1 alleles have spread in populations and contribute to the understanding of natural selection.

Allele and genotype frequencies of CR1 variants in exon 29 [rs17259045, rs41274768 (Knα/b), rs17047660 (McCα/b), rs17047661 (Sl1/Sl2), rs4844609 (Sl4/Sl5), rs6691117 (KCAM+/-)] as well as their haplotype frequencies were differently distributed among the Brazilian, Vietnamese, Indian, Congolese and Ghanaian study groups. So far, the frequencies of these variants and especially, the distribution of blood group antigens have not been described explicitly for central African populations yet.

CR1 variants rs17047660A/G (McCα/b) and rs17047661A/G (Sl1/Sl2) were observed to be polymorphic only in the African groups compared to those from Asia and Brazil, indicating that the frequencies of these two SNPs result from a strong selective bias exerted by exposure...
to distinct pathogens especially by *Plasmodium falciparum*. This is substantiated by a high linkage disequilibrium between the two variants. Of the reconstructed CR1 haplotypes, CR1*AGAGTG* and CR1*AGGGTG* were observed to be unique among the Congolese and Ghanaian groups. CR1*AGAGTG* contains the allele of the rs17047660A. This locus also determines the Knops blood group antigen McC\textsuperscript{ab}. Studies have demonstrated that this blood group antigen is dominant among many ethnic groups of African ancestry living in malaria endemic regions [34].

Higher rates of adaptive evolution are expected to occur especially in genes involved in the immune system, as these gene loci coevolve with pathogens. This is largely contributed by two factors the genetics of the population and natural selection. Immune genes tend to evolve rapidly as selection pressure is changing continuously due to various pathogenic challenges. Therefore, positive selection of rs17047660A/G (McC\textsuperscript{ab}) and rs1704661A/G (Sl1/Sl2) loci is expected in sub-Saharan African populations exposed to distinct pathogenic challenges (e.g. *falciparum* malaria). Such a selective advantage occurs mainly in immune genes involved in pathogen recognition and signaling, and the CR1 is one of such genes involved in innate immunity.

In addition, the reported frequencies of these two loci, rs17047660A/G (Sl4/Sl5) and rs1704661A/G (Sl1/Sl2), in this study were in accordance with frequencies observed in other East and West African ethnicities as reported in the 1000 Genomes database (https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes). The frequencies in other African populations correspond to the frequencies observed in this study [rs17047660A/G (McC\textsuperscript{ab}): Gambian 0.67/0.32, Kenyan 0.69/0.31, Sierra Leone 0.71/0.29 and Yoruba 0.73/0.27; whereas for rs17047661A/G (Sl1/Sl2): Gambian 0.21/0.78, Kenyan 0.30/0.70, Sierra Leone 0.21/0.79 and Yoruba 0.30/0.70]. Also the reported frequencies in other studied Asian and Brazilian populations were in accordance with the frequencies described in the 1000 Genomes database.

There is growing evidence of ethnic differences in susceptibility to some infectious diseases and of genetic adaptation to diverse pathogens [18,35]. This study investigated five antigens of the Knops blood group including the Knops (rs41274768, Kn\textsuperscript{ab}, p.N1540S), the McCoy (rs17047660, McC\textsuperscript{ab}, p.K1590E), the Swain-Langley/Villien (rs17047661, Sl1/Sl2, p.R1601G), the Swain-Langley (rs4844609, Sl4/Sl5, p.T1610S), and the KCAM antigens (rs6691117, KCAM+/-, p.I1615V) [19–23]. These Knops blood group polymorphisms have been found associated with various infectious diseases (Table 4). In particular, the two Knops blood group variants McC\textsuperscript{b} (rs1704660G, E1590K) and Sl2 (rs1704661G, R1601G) have specific distributions among African populations, which has been related to selective pressure by malaria in Africa [36–42]. The substitution of lysine to glutamic acid at 1590 aa position modulates the epitope conformation and serologic reactivity due to its surface exposed feature, affecting the overall CR1 binding capacity [22]. A high frequency of the rs1704661G (Sl2) allele was observed in the African groups. The high frequency of the rs6691117G (KCAM-, I1615V) allele in Africa and India indicates that this allele, similar as the rs1704660G (McC\textsuperscript{b}) and rs1704661G (Sl2) alleles, might also be subjected to selection. The presence of rs1704661G (McC\textsuperscript{b}), which is almost limited to African populations, suggests that rs1704661A (Sl1) may be the ancestral allele [43]. Also a differential distribution of rs6691117A/G (KCAM+/-) variants was observed. For instance, in the Vietnamese and Brazilian groups, rs6691117A (KCAM+) is a major allele, while the variant rs6691117G (KCAM-) was observed to be the major allele in Africa. A study from India compared exon 29 CR1 variants in endemic and non-endemic populations and concluded that a differential association with falciparum malaria in regions of varying disease endemicity exists [44]. However, the Indian samples from the present study originate from an area not endemic for malaria.
Taken together, this study revealed significant differences in allele, genotype and haplotype frequencies of CR1 SNPs in five populations. A limitation of this study might be a small sample size. However, this study, first to include population from Central Africa, may provide an increased understanding of the contribution of red blood cell phenotypes and the complement regulator protein with regard to possible associations with infectious diseases. Further studies are warranted with increased sample sizes, to determine the role of CR1 in disease associations and pathogenesis mechanisms.

**Acknowledgments**

The authors thank all the study participants. They also thank the staff of all the hospitals and institutions involved in this study for their support.

**Author Contributions**

**Conceptualization**: TPV.

**Data curation**: TLS SA DPG CNN.

**Formal analysis**: TLS FAA HVT.

**Funding acquisition**: PGK TPV.

**Investigation**: TLS SA DPG CNN.

**Resources**: NLT LHS PE KT VLL FN IJMR.

**Supervision**: TPV.

**Writing – original draft**: TLS TPV.

**Writing – review & editing**: CGM TPV HVT.
References

1. Liu D, Niu ZX (2009) The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35). Immunopharmacol Immunotoxicol 31: 524–535. https://doi.org/10.3109/08923970902845768 PMID: 19874218

2. Holers VM (2014) Complement and its receptors: new insights into human disease. Annu Rev Immunol 32: 433–459. https://doi.org/10.1146/annurev-immunol-032713-120154 PMID: 24499275

3. Jacquet M, Lacroix M, Ancelet S, Gout E, Gaboriaud C, Thielens NM et al. (2013) Deciphering complement receptor type 1 interactions with recognition proteins of the lectin complement pathway. J Immunol 190: 3721–3731. https://doi.org/10.4049/jimmunol.1202451 PMID: 23460739

4. Weis JH, Morton CC, Bruns GA, Weis JJ, Klickstein LB, Wong WW et al. (1987) A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol 138: 312–315. PMID: 3782802

5. Klop B, van der Pol P, van BR, Wang Y, de Vries MA, van SS et al. (2014) Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1. J Biol Chem 289: 35421–35430. https://doi.org/10.1074/jbc.M114.573840 PMID: 25349208

6. Aiyaz M, Lupton MK, Proitsi P, Powell JF, Lovestone S (2012) Complement activation as a biomarker for Alzheimer’s disease. Immunobiology 217: 204–215. https://doi.org/10.1016/j.imbio.2011.07.023 PMID: 21856034

7. Hourcade D, Miesner DR, Atkinson JP, Holers VM (1988) Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J Exp Med 168: 1255–1270. PMID: 2971757

8. Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT (1987) Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med 165: 1095–1112. PMID: 2951479

9. Erdei A, Isaak A, Torok K, Sandor N, Kremlitzka M, Prechl J et al. (2009) Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. Mol Immunol 46: 2767–2773. https://doi.org/10.1016/j.molimm.2009.05.181 PMID: 19559484

10. Fang Y, Xu C, Fu YX, Holers VM, Molina H (1998) Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 160: 5273–5279. PMID: 9605124

11. Weiss L, Fischer E, Haeffner-Cavaillon N, Jouvin MH, Appay MD, Barlet J et al. (1989) The human C3b receptor (CR1). Adv Nephrol Necker Hosp 18: 249–269. PMID: 2522267

12. Meholph E, Whitby K, Oliphant T, Mani A, Engle M, Diamond MS (2005) Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 79: 7466–7477. https://doi.org/10.1128/JVI.79.12.7466-7477.2005 PMID: 15919902

13. Haas KM, Toapanta FR, Officer JA, Poe JC, Weis JH, Karp DR et al. (2004) Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol 172: 5833–5837. PMID: 15128761

14. Hellwage J, Jokiranta TS, Friese MA, Wolk TU, Kampen E, Zipfel PF et al. (2002) Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol 169: 6935–6944. PMID: 12471127

15. Hinton PR, Xiong JM, Johlfgs MG, Tang MT, Keller S, Tsurushita N (2006) An engineered human IgG1 antibody with longer serum half-life. J Immunol 176: 346–356. PMID: 16365427

16. Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT (1988) Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 168: 1699–1717. PMID: 2972794

17. Saranya B, Saxena S, Saravanan KM, Shikila H (2016) Comparative Analysis of the Molecular Adjuvants and Their Binding Efficiency with CR1. Interdiscip Sci 8: 35–40. https://doi.org/10.1007/s12539-015-0279-4 PMID: 26394056

18. Krych-Goldberg M, Atkinson JP (2001) Structure-function relationships of complement receptor type 1. Immunol Rev 180: 112–122. PMID: 11414353

19. Moulds JM, Zimmerman PA, Dounombo OK, Diai DA, Atkinson JP, Krych-Goldberg M et al. (2002) Expansion of the Knops blood group system and subdivision of Si(a). Transfusion 42: 251–256. PMID: 11896343

20. Moulds JM, Kassambara L, Middleton JJ, Baby M, Sagara I, Guindo A et al. (2000) Identification of complement receptor one (CR1) polymorphisms in west Africa. Genes Immun 1: 325–329. https://doi.org/10.1038/sj.gene.6363767 PMID: 11196694
21. Moulds JM, Thomas BJ, Doumbo O, Diallo DA, Lyke KE, Plowe CV et al. (2004) Identification of the Kna/Knb polymorphism and a method for Knops genotyping. Transfusion 44: 164–169. PMID: 14962306

22. Moulds JM, Zimmerman PA, Doumbo OK, Kassambara L, Sagara I, Diallo DA et al. (2001) Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1. Blood 97: 2879–2885. PMID: 11313284

23. Moulds JM (2010) The Knops blood-group system: a review. Immunohematology 26: 2–7. PMID: 20795311

24. Fernie-King B, Seilly DJ, Davies A, Lachmann PJ (2002) Subversion of the innate immune response by micro-organisms. Ann Rheum Dis 61 Suppl 2: ii8–12.

25. Dominguez M, Moreno I, Aizpurua C, Torano A (2003) Early mechanisms of Leishmania infection in human blood. Microbes Infect 5: 507–513. PMID: 12758280

26. Chakraborty P, Ghosh D, Basu MK (2001) Modulation of macrophage mannose receptor affects the uptake of virulent and avirulent Leishmania donovani promastigotes. J Parasitol 87: 1023–1027. https://doi.org/10.1645/0022-3395(2001)087[1023:MO-MMRA]2.0.CO;2 PMID: 11695359

27. Dominguez M, Moreno I, Lopez-Trascasas M, Torano A (2002) Complement interaction with trypanosomatid promastigotes in normal human serum. J Exp Med 195: 451–459. https://doi.org/10.1084/jem.20011319 PMID: 11854358

28. Gomes JA, Campi-Azevedo AC, Teixeira-Carvalho A, Silveira-Lemos D, Vitelli-Avelar D, Sathler-Avelar R et al. (2012) Impaired phagocytic capacity driven by downregulation of major phagocytosis-related cell surface molecules elicits an overall modulatory cytokine profile in neutrophils and monocytes from the indeterminate clinical form of Chagas disease. Immunobiology 217: 1005–1016. https://doi.org/10.1016/j.imbio.2012.01.014 PMID: 22387073

29. Gomes JA, Campi-Azevedo AC, Teixeira-Carvalho A, Silveira-Lemos D, Vitelli-Avelar D, Sathler-Avelar R et al. (2012) Impaired phagocytic capacity driven by downregulation of major phagocytosis-related cell surface molecules elicits an overall modulatory cytokine profile in neutrophils and monocytes from the indeterminate clinical form of Chagas disease. Immunobiology 217: 1005–1016. https://doi.org/10.1016/j.imbio.2012.01.014 PMID: 22387073

30. Ogembo JG, Kannan L, Ghiran I, Nicholson-Weller A, Finberg RW, Tsokos GC et al. (2013) Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor. Cell Rep 3: 371–385. https://doi.org/10.1016/j.celrep.2013.01.023 PMID: 23416052

31. Beck Z, Brown BK, Wieczorek L, Peachman KK, Matyas GR, Polonis VR et al. (2009) Human erythrocytes selectively bind and enrich infectious HIV-1 virions. PLoS One 4: e8297. https://doi.org/10.1371/journal.pone.0008297 PMID: 20011536

32. Horakova E, Gasser O, Sadallah S, Inal JM, Bourgeois G, Ziegau I et al. (2004) Complement mediates the binding of HIV to erythrocytes. J Immunol 173: 4236–4241. PMID: 15356175

33. Wang FS, Chu FL, Jin L, Li YG, Zhang Z, Xu D et al. (2005) Acquired but reversible loss of erythrocyte complement receptor 1 (CR1, CD35) and its longitudinal alteration in patients with severe acute respiratory syndrome. J Exp Med 195: 451–459. https://doi.org/10.1084/jem.20011319 PMID: 20011536

34. Seregin SS, Aldhamen YA, Appledorn DM, Schuld NJ, McBride AJ, Bujold M et al. (2009) CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies. Gene Ther 16: 1245–1259. https://doi.org/10.1038/gt.2009.77 PMID: 19554032

35. Tettey R, Ayeh-Kumi P, Tettey P, Adjei GO, Asmah RH, Dodoo D (2015) Severity of malaria in relation to a complement receptor 1 polymorphism: a case-control study. Pathog Glob Health 109: 247–252. https://doi.org/10.1179/2047773215Y.0000000011 PMID: 25916414

36. Krych-Goldberg M, Moulds JM, Atkinson JP (2002) Human complement receptor type 1 (CR1) binds to a major malarial adhesin. Trends Mol Med 8: 531–537. PMID: 12421687

37. Apinjoh TO, Anchanng-Kimbi JK, Nghia-Yafi C, Ngwai AN, Mugir RN, Clark TG et al. (2014) Association of candidate gene polymorphisms and TGF-beta/IL-10 levels with malaria in three regions of Cameroon: a case-control study. Malar J 13: 236. https://doi.org/10.1186/1475-2875-13-236 PMID: 24934404

38. Diakite M, Achidi EA, Achouduh O, Craik R, Djimde AA, Evehe MS et al. (2011) Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites. Malar J 10: 250. https://doi.org/10.1186/1475-2875-10-250 PMID: 21867552

39. Duru KC, Noble JA, Guindo A, Yi L, Imumorin IG, Diallo DA et al. (2015) Extensive genomic variability of knops blood group polymorphisms is associated with sickle cell disease in Africa. Evol Bioinform Online 11: 25–33. https://doi.org/10.4137/EBO.S23132 PMID: 25788827

40. Eid NA, Hussein AA, Elzein AM, Mohamed HS, Rockett K, Kwiatkowski DP et al. (2010) Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring. Malar J 9: 119. https://doi.org/10.1186/1475-2875-9-119 PMID: 20459687

41. Kariuki SM, Rockett K, Clark TG, Reyburn H, Agbenyega T, Taylor TE et al. (2013) The genetic risk of acute seizures in African children with falciparum malaria. Epilepsia 54: 990–1001. https://doi.org/10.1111/epi.12173 PMID: 23614351
41. Rowe JA, Claessens A, Corrigan RA, Arman M (2009) Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Rev Mol Med 11: e16. https://doi.org/10.1017/S1462399409001082 PMID: 19467172

42. Toure O, Konate S, Sissoko S, Niangaly A, Barry A, Sall AH et al. (2012) Candidate polymorphisms and severe malaria in a Malian population. PLoS One 7: e43987. https://doi.org/10.1371/journal.pone.0043987 PMID: 22957039

43. Zimmerman PA, Fitness J, Moulds JM, McNamara DT, Kasehagen LJ, Rowe JA et al. (2003) CR1 Knops blood group alleles are not associated with severe malaria in the Gambia. Genes Immun 4: 368–373. https://doi.org/10.1038/sj.gene.6363980 PMID: 12847553

44. Sinha S, Jha GN, Anand P, Qidwai T, Pati SS, Mohanty S et al. (2009) CR1 levels and gene polymorphisms exhibit differential association with falciparum malaria in regions of varying disease endemicity. Hum Immunol 70: 244–250. https://doi.org/10.1016/j.huimm.2009.02.001 PMID: 19480840

45. Holton P, Ryten M, Nalls M, Trabzuni D, Weale ME, Hernandez D et al. (2013) Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet 77: 85–105. https://doi.org/10.1111/ahg.12000 PMID: 23360175

46. Noumsi GT, Tounkara A, Diallo H, Billingsley K, Moulds JJ, Moulds JM (2011) Knops blood group polymorphism and susceptibility to Mycobacterium tuberculosis infection. Transfusion 51: 2462–2469. https://doi.org/10.1111/j.1537-2995.2011.03161.x PMID: 21569042

47. Fitness J, Tosh K, Hill AV (2002) Genetics of susceptibility to leprosy. Genes Immun 3: 441–453. https://doi.org/10.1038/sj.gene.6363926 PMID: 12486602

48. Ren N, Kuang YM, Tang QL, Cheng L, Zhang CH, Yang ZQ et al. (2015) High Incidence of Malaria Along the Sino-Burmese Border Is Associated With Polymorphisms of CR1, IL-1A, IL-4R, IL-4, NOS, and TNF, But Not With G6PD Deficiency. Medicine (Baltimore) 94: e1681.

49. Fonseca MI, Chu S, Pierce AL, Brubaker WD, Hauhart RE, Mastroeni D et al. (2016) Analysis of the Putative Role of CR1 in Alzheimer’s Disease: Genetic Association, Expression and Function. PLoS One 11: e0149792. https://doi.org/10.1371/journal.pone.0149792 PMID: 26914463

50. Malik M, Parikh I, Vasquez JB, Smith C, Tai L, Bu G et al. (2015) Genetic ignition focus on microglial inflammation in Alzheimer’s disease. Mol Neurodegener 10: 52. https://doi.org/10.1186/s13024-015-0048-1 PMID: 26438529

51. Sherif FF, Zayed N, Fakhr M (2015) Discovering Alzheimer Genetic Biomarkers Using Bayesian Networks. Adv Bioinformatics 2015: 639367. https://doi.org/10.1155/2015/639367 PMID: 26366461

52. Van CC, Bettens K, Engelborghs S, Vandenbulcke M, Van DJ, Vermeulen S et al. (2013) Complement receptor 1 coding variant p.Ser1610Thr in Alzheimer’s disease and related endophenotypes. Neurobiol Aging 34: 2235–2236.

53. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H (2013) Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet 132: 1077–1130. https://doi.org/10.1007/s00439-013-1331-2 PMID: 23820649

54. Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D, Sabuncu MR et al. (2012) A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum Mol Genet 21: 2377–2388. https://doi.org/10.1039/hmg/dd5054 PMID: 22343410

55. Kullo IJ, Ding K, Shameer K, McCarty CA, Jarvik GP, Denny JC et al. (2011) Complement receptor 1 gene variants are associated with erythrocyte sedimentation rate. Am J Hum Genet 89: 131–138. https://doi.org/10.1016/j.ajhg.2011.05.019 PMID: 21700265

56. Jiao B, Liu X, Zhou L, Wang MH, Zhou Y, Xiao T et al. (2015) Polygenic Analysis of Late-Onset Alzheimer’s Disease from Mainland China. PLoS One 10: e0144898. https://doi.org/10.1371/journal.pone.0144898 PMID: 26680604

57. Zhao L, Zhang Z, Lin J, Cao L, He B, Han S et al. (2015) Complement receptor 1 genetic variants contribute to the susceptibility to gastric cancer in Chinese population. J Cancer 6: 525–530. https://doi.org/10.7150/jca.10749 PMID: 2600043

58. Yu X, Rao J, Lin J, Zhang Z, Cao L, Zhang X (2014) Tag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancer. Mol Cancer 13: 56. https://doi.org/10.1186/1476-4588-13-56 PMID: 24621201

59. Backes C, Harz C, Fischer U, Schmitt J, Ludwig N, Petersen BS et al. (2015) New insights into the genetics of glioblastoma multiforme by familial exome sequencing. Oncotarget 6: 5918–5931. https://doi.org/10.18632/oncotarget.2950 PMID: 25537509

60. McElroy JJ, Gutman CE, Shaffer CM, Busch TD, Puttonen H, Teramo K et al. (2013) Maternal coding variants in complement receptor 1 and spontaneous idiopathic preterm birth. Hum Genet 132: 935–942. https://doi.org/10.1007/s00439-013-1304-5 PMID: 23591632